

## Index

### a

aberration 256  
 – assay 256  
 absorption  
 – assay 49  
 – prediction of *in vivo* absorption 135  
 accessibility 119  
 accuracy 105  
 acetaminophen (APAP) 147, 373  
 acetanilide 147  
 active transport 51  
 active transporter 119  
 – cell model 123  
 acyl glucuronide (AG) 152  
 ADME (absorption, distribution, metabolism,  
 and excretion)/Tox (ADMET) 3ff.  
 – assay 6ff.  
 – materials for screening 14f.  
 – methods 16ff.  
 ADMET Predictor 131  
 advanced compartmental absorption and  
 transit (ACAT) model 121, 224  
 advanced drug absorption and metabolism  
 (ADAM) model 121, 224  
 adverse drug reaction (ADR) 44, 58, 149,  
 315  
 – bone marrow toxicity (BMT) 433  
 – classification 150, 276  
 – *in silico* prediction 298  
 adverse immune effect 439ff.  
 – profiling 439ff.  
 adverse reaction enzyme 280  
 aggregation 83ff.  
 – partitioning 87  
 – solubility 83  
 aggregation number 88  
 alanine aminotransferase (ALT) 369ff.  
 ALIAS 22  
 alkaline phosphatase (ALP) 369ff.

### allergy

– *in vitro* assay 452  
 – testing for induction 445  
 AlogP 307  
 ALOGPS method 96, 307  
 Ames test 251ff.  
 – photo-Ames test 480  
 – variant 255  
 aneuploidy 245  
 antibiotics 33  
 area under the first moment curve (AUMC)  
 208  
 area under the plasma concentration–time  
 curve (AUC) 198, 291  
 aromatic hydrocarbon, halogenated 450  
 aromatic/aryl hydrocarbon receptor (AhR)  
 418, 450  
 artificial membrane 125, 134  
 aspartate aminotransferase (AST) 369ff.  
 assay robustness 48  
 assay validation 47  
 atabrine 148  
 attrition 326  
 – rate 308  
 autoimmunity, testing for induction 446  
 autoimmunity potential, evaluation of  
 chemicals 447  
 azithromycin 33

### b

barrier solubility diffusion theory 126  
 basic absorption assay 49  
 bile acid 365  
 bile acid salt 89  
 bile salt efflux protein (BSEP) 365  
 – *in vitro* and *in vivo* measurement of  
 inhibition 365  
 – inhibition 368  
 binding assay 284

- bioactivation 151, 349ff.
  - bioactivation potential 347ff
  - cytochrome P450-mediated 355
- bioactivity spectra, data mining 314
- BioEpisteme 252
- biological dialysis 205
- biomarker 369ff.
  - discovery 372
  - *ex vivo* 443
  - hepatotoxicity 369ff
  - immune suppression 443
  - immunotoxicity 452ff.
  - *in vitro* 373, 452
  - *in vivo* 373, 443
  - safety 329
  - validation 374
- Biopharmaceutics Classification Scheme (BCS) 49
- BioPrint 60
  - database 300
- bis(tri-*n*-butyl)tin oxide (TBTO) 456
- blood brain barrier (BBB)
  - brain-penetration 45
  - cell culture model 122
- bone marrow toxicity (BMT) 433
- Boudinot equation 204
- broad safety 280
  
- c**
- <sup>14</sup>C cyanide trapping 157
- C10-tetraethylammonium (C10-TEA) 398f.
- CACO-2 cell 121
  - assay 7, 29, 51
- calcium channel, L-type 390ff.
- candidate selection 351
- capillary electrophoresis (CE) 104
- cardiosafety 387ff.
  - cardiosafety assessment 401ff.
  - cardiotoxicity 326
  - nonclinical assay 396
  - non-hERG ion channel assay 395
- cell biology 6
- cell death, measurement 330
- cell model
  - active transporter 123
  - *in vivo* brain penetration 124
  - toxicity 331
- cell mutation test, mammalian 256
- cell-free competition binding assay 392
- cellular dielectric spectroscopy (CDS) 292
- chemical database, data mining 314
- chemical profiling 305
- chemical sensitization 454
  - *in vitro* cell culture 454
- chemogenomics database 309
- ChemSpider 316
- cholestasis, drug-induced 365ff.
- cholestatic injury 370
- chromatographic hydrophobicity index (CHI) 102
- chromatographic method 100
- chromosomal aberration (CA), photoinduced 485
- chromosome damage 256
  - assay 262
- clastogenesis 245
- clearance 213
- clinical candidate (CC) 290
- Cloe PK 224
- clofilium 398
- ClogP method 94
- CNS (central nervous system) 45
- coenzyme A (CoA), depletion 360
- comet assay 258, 488
- complete bioactivity data matrix 298
- complete data matrix 298
- compound
  - management 5
  - profile 42
  - profiling 415ff.
  - *in silico* tool 307
  - *in vitro* and *ex vivo* 415ff.
  - prediction 304ff.
  - promiscuity 303ff.
- computational approach 130
- CoMSIA (conformational analysis and molecular alignment) approach 133
- $\pi$ -constant method 92
- constant neutral loss (CNL) 156
- constitutive androstane receptor (CAR) 177ff.
- contact dermatitis (CD) 445
- contract research organization (CRO) 280, 482
- covalent binding 154
  - determination 348
  - detoxification 154
  - liver microsome 157
  - non-toxicological 154
  - study 348
- cutaneous reaction, immune-mediated 153
- CYP enzyme, *see* cytochrome P450
  - inhibition screen 170
  - inhibitor 171ff.
- cyclosporine 32
- cytochrome P450 (CYP enzyme) 148, 168
  - assay 7ff.
  - recombinant human 181

- cytokine 454
  - cytotoxicity 325ff.
    - acute 331
    - assay 335
    - biomarker 335
    - *in vitro*, *see in vitro* cytotoxicity
    - marked 331
    - sublethal 331
  - cytotoxicity assessment 329
  - cytotoxicity testing 340
- d**
- danger hypothesis 153
  - data analysis 18, 305
  - data matrix 298
  - data mining 59
  - data reporting 59
  - database 311
    - similarity search 313
    - target prediction 312
    - web-based 278
  - DDI, *see* drug–drug interaction
  - degree of flatness (DF) 120
  - delayed type hypersensitivity (DTH) 445
  - dendritic cell (DC) 454f.
  - DEREK 35, 251, 347, 451, 475
  - detection and analysis 17
  - detoxication 350
    - covalent binding 154
  - development candidate (DC) 287
  - dexfenfluramine 274
  - diffusion coefficient 86
  - DILI (drug-induced liver injury) 57, 356ff.
  - dilution range 249
  - discovery cytotoxicology 329
  - discovery safety assessment 327
  - discovery screening 326
  - discovery toxicology screening 325ff.
  - dissolution 86
  - distribution 51
  - distribution coefficient 98f.
  - DMPK (drug metabolism and pharmacokinetics)
    - testing strategy 8
    - workflow 4
  - DNA adduct assessment 258
  - dofetilide 399
  - dose 248
  - drug candidate, hepatotoxic potential 348
  - drug delivery 43
  - drug design, volume of distribution 208
  - drug discovery
    - candidate selection 351
    - covalent binding study 348
      - HCA cytotoxicity testing 339
      - *in vitro* safety pharmacology profiling 287
      - PAMPA (parallel artificial membrane assay) 127
      - PBPK (physiologically based pharmacokinetic) model 226
      - PK/PD model 227
      - reactive metabolite trapping 348
  - drug discovery process
    - challenge 221
    - delivery 43
    - drug-likeness 35
  - drug metabolism 145ff.
    - prediction 149
  - drug–drug interaction (DDI) 53, 165ff., 179
    - assessment of risk 165
    - cocktail assay 173
    - *in silico* modelling 167
    - magnitude 184f.
    - perpetrator 169ff., 183
    - plasma protein binding 197ff.
    - prediction 182
    - screening for liability 165
    - single point 172
  - drug-induced liver injury, *see* DILI
  - drug-likeness
    - computational prediction 26
    - filter 35
    - natural product 32
    - prediction 25ff.
  - DrugBank 316
- e**
- E-state descriptor 95
  - effective parameter 334
  - efficacious free plasma concentration (EFPC) 403f.
  - efficacy 105
    - screening 329
  - efflux 51
  - efflux ratio (ER) 53
  - electrochemical oxidation 158
  - electron transport system (ETS) 357
  - elimination 51
  - empirical rule 30
  - environment and management 19
  - enzyme induction 176
  - enzyme inhibition 169ff.
  - equilibrium dialysis 204
  - ex vivo* compound profiling 415ff.
  - ex vivo* covalent binding 157
  - experimental filtering 98

- exposure
  - assay 49
  - plasma protein binding 197ff.

**f**

- fatty acid  $\beta$ -oxidation 360
- felbamate 349
- fenfluramine 274
- fexofenadine 62
- fialuridine 275
- flip-flop model 126
- fluorescent inhibition screen 172
- fluorescent polarization (FP) 284, 392f.
- fluorescence resonance transfer (FRET) 284
- fluorofelbamate 349
- fold expansion (FE) 119
- fraction absorbed data 124
- 2D fragmental approach 92ff.
- free radical 152
- functional assay 284
- functional parameter 333

**g**

- gastrointestinal transit absorption model (GITA) 121
- GastroPlus 131, 224ff.
- gene expression assay 259
  - eukaryotic 259
  - prokaryotic 259
- gene mutation assay 254ff.
- general safety profile 280
- general side effect profile 280
- general solubility equality (GSE) 30
- genetic toxicity (genotoxicity) 57, 243ff., 264
- genotoxicity assay, screening 253
- genotoxicity assessment 250ff.
- genotoxicity profiling 248, 263
- genotoxicity testing 246
- genotoxin 245
- Gibbs–Donnan effect 204
- glutathione (GSH) 151
  - conjugate 151
  - glutathione-S-transferase (GST) 151
  - mass spectrometric detection 155
- GPCR (G protein coupled receptor) 34, 307
- growth arrest and DNA damage, *see* GADD

**h**

- H bonding 30
- HAART (highly active antiretroviral therapy) treatment 360ff.
- hapten hypothesis 153
- HCA cell model 337
- HCA cytotoxicity assay 338

- drug discovery 339
- HCS cytotoxicity assay 340f.
- hematotoxicity 415ff.
  - inducing compound 416
  - potential 417
  - testing 419ff., 431
- hepatocellular injury 370
- hepatotoxic potential
  - covalent binding study 348
  - reactive metabolite trapping 348
- hepatotoxicity 57, 326
  - idiosyncratic 337
  - mitochondrial 275
  - predicting drug-induced 345ff.
- hERG (human ether-a-go-go related gene) channel 35, 56ff., 388ff.
  - blocker 299, 399
  - CoMFA model 400
  - computational model 398
  - CoMSiA model 401
  - GRIND model 401
  - homology model 399
  - hypothesis 298
  - inhibition 387ff.
  - patch clamp assay 396
  - pharmacophore model 398
  - profiling assay 391
  - QSAR model 400
- hierarchical testing, concept 46
- high content screening (HCS) 7
- high throughput induction assay 179
- high throughput screening (HTS) 25ff., 98, 284
  - *in vitro* 104
- Hildebrand parameter 77
- hit
  - collection 98
  - profiling 265
- hit and lead profiling 264
  - *in silico* method 252
  - *in vitro* approach 243ff.
- hit rate parameter 305
- hit-to-lead *in silico* profiling 135
- hit-to-lead phase 287
- hormesis 338
- human equilibrative nucleoside transporter (hENT1, adenosine transporter) 275
- human leukocyte antigen (HLA)-haplotype 448
- human toxicity data 336
  - validation 336
- hydrophilic interaction liquid chromatography (HILIC) 103
- hydrophobicity 103

## i

ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) guideline 247ff., 440

idiosyncratic drug reaction (IDR) 150

idiosyncratic liver injury, *see* liver injury

idiosyncratic toxicity 153

immobilized artificial membrane (IAM) 102

immune system 439ff.  
– toxicity study 443

immunostimulation 450

immunosuppression 453  
– gene profiling 453  
– *in vitro* assay 452

immunotoxicity/immunotoxicology 439ff.  
– biomarker 452ff.  
– chemicals 441  
– detection 442ff.  
– *in silico* approach 451  
– *in vitro* approach 451  
– structure 449  
– target organ and cell 458

immunotoxicogenomics 456

*in silico* assessment 250  
– genotoxicity assessment 250

*in silico* intestinal device (ISID) 131

*in silico* modeling 130ff.  
– drug–drug interaction (DDI) 167

*in silico* prediction 92  
– adverse reaction 298  
– human VD 213  
– phototoxicity 474  
– plasma protein binding (PPB) 206

*in silico* safety profiling 303

*in silico* target fishing 313

*in vitro* assay 49, 59  
– limitation 128  
– species specificity 58

*in vitro* assessment 360

*in vitro* cellular membrane system 132

*in vitro* compound profiling 415ff.

*in vitro* cytotoxicity 325ff.

*in vitro* metabolism 146  
– system 149

*in vitro* photogenotoxicity testing 483

*in vitro* phototoxicity testing 471ff.

*in vitro* reactive metabolite trapping study 347

*in vitro* safety pharmacology 273ff.  
– computational approach 297ff.  
– knowledge-based 297ff.  
– profiling 273ff.  
– safety profiling assay 280

*in vitro*–*in vivo* extrapolation 119

*in vivo* assessment 360

*in vivo* brain penetration 124

*in vivo* model 260

*in vivo* profiling 264

*in vivo* system 130

*in vivo* toleration (IVT) study 327

indicator variable 134

indirect acting agent 245

inhibition  
– chemical 180  
– competitive 169  
– IC<sub>50</sub> 172  
– mechanism-based (MBI) 169ff.

intestinal cell culture model 121

intestinal membrane 118

intrinsic clearance 186

ion channel 389ff.

ionic species, prediction 97

iterative assay 54

IVIVC (*in vitro*/*in vivo* correlations) 53

## l

LC/MS (liquid chromatography/mass spectrometry) 7

lead identification 227

lead optimization 231, 287  
– profiling 266

lead profiling 7

lead selection 287  
– clinical 235

LeadProfilingScreen 280

library, profiling 265

ligand 34

ligand binding assay 177

LIMS (laboratory information management system) 21

linear free energy relationship (LFER) 96

Lipinski's rule of five 30

lipophilicity 92, 106  
– coefficient 92  
– 3D lipophilicity prediction 107  
– neutral substance 92

liquid handlers 17

liver injury, idiosyncratic 364ff.

liver microsome 157  
– covalent binding 157

local lymph node assay (LLNA) 445

long QT (LQT) syndrome 387ff.

## m

machine learning 26  
– algorithm 29

mammalian cell mutation test 256

MAO (monoamine oxidase) inhibitor 275

- mass spectrometric detection 155
  - materials for screening 14f.
  - MATLAB 225
  - MC4PC 252
  - MCASE 251
  - MDCK (Madin–Darby Canine Kidney) cell line 122
  - MDLmolfile standard 34
  - MDL-QSAR 252
  - mean residence time (MRT) 210
  - mechanism of action (MOA) 313
  - mechanism-based inhibition (MBI) 169ff.
  - membrane
    - binding 129
    - permeability 118
    - permeation 117
    - structure, physiology, and chemistry 117
  - membrane potential-sensitive fluorescent dye 394
  - mercapturic acid 155
  - meta analysis, safety pharmacology 304
  - metabolic intermediate complex (MIC) 169
  - metabolic stability assay 7
  - metabolism 51
    - hepatic 62
  - metabolite
    - electrophilic 151
    - measurement of reactive metabolite 155
    - reactive 153ff., 346
  - Metafer MSearch 257
  - MetaSite 347
  - method 16
    - ADME/Tox screening 20
  - 5-methoxypsoralene (5-MOP) 476, 485
  - 8-methoxypsoralene (8-MOP) 476, 483
  - microfluidics 17
  - micronuclei 257
  - microsome 149ff.
  - mitochondrial DNA (mtDNA) 359ff.
    - synthesis 359
  - mitochondrial dysfunction, drug-induced 360
  - mitochondrial permeability transition pore (MPT) 359
  - mitochondrial protein synthesis 359
  - mitochondrial respiration, uncoupler 358
  - mitochondrial target 334
  - mitochondrial toxicity 356
  - MLOGP method 95
  - molecular field interaction (MIF) 107
  - molecular group surface area approach (MGSA) model 78
  - molecular hologram 26
  - molecular lipophilicity potential (MLP) 95
  - molecular mechanics (MM) 134
  - morphological parameter 333
  - mouse lymphoma assay 254
  - MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 486ff.
  - multi-parameter optimization (MPO) 168
  - MULTICASE 35
  - mutagenesis 245
- n**
- NCE, *see* new chemical entity
  - neomycine 33
  - new chemical entity (NCE) 98, 165
  - no observed adverse effect level (NOAEL) 375
  - non-aqueous solvent, solubility 78
  - non-hERG ion channel assay 395
  - non-steroidal anti-inflammatory drug (NSAID) 358, 418
  - nuclear magnetic resonance (NMR) technique 362
  - nucleophile
    - hard 155
    - soft 155
  - nucleotide reverse transcriptase inhibitor (NRTI) 359f.
- o**
- OCT-PAMPA 99
  - octanol-water partition coefficient 30, 125
  - ochratoxin A (OTA) 199
  - off-target effect 291
  - organic anion transporter (OATP) 199
  - oxidative phosphorylation (OXPHOS) 356ff.
    - inhibition 358
  - oxidative stress 152, 363
    - measurement 363
    - source 363
- p**
- PAMPA (parallel artificial membrane permeability assay) 99, 126, 205
    - measurement 10, 29
    - variation 127
  - paracellular pathway 118ff.
  - paroxetine 350
  - partition 125
  - partition coefficient 92
    - measurement technique 106
  - partitioning 87
  - passive transcellular pathway 117
  - passive transcellular permeability 119
  - PBPK, *see* physiologically based pharmacokinetics
  - peace pill 274

- penetration, brain 45  
 peptide transporter PEPT1 130ff.  
 permeability 49  
   – UWL 128  
 permeability assay 7, 50  
 permeation 125  
 P-glycoprotein (P-gp) 51  
 pH partition theory 118  
 pharmacological promiscuity, clinical interpretation 288  
 phospholipid vesicle PAMPA 127  
 phospholipid–octanol PAMPA 127  
 photo irritation factor (PIF) 482  
 photo red blood cells test (photo-RBC test) 479  
 photo-Ames test 480  
 photo-cleavage, isolated plasmid DNA 479  
 photoallergy 471  
 photocytotoxicity 481  
 photogenotoxicity 471, 481ff.  
 photoirritation potential 481  
   – 3T3 NRU assay 481ff.  
 photomutagenesis assessment  
   – microbiological model 480  
   – yeast model 480  
 photoreactivity, *in tubo* 478  
 phototoxic compound 476f.  
 phototoxicity/photoinduced toxicity 57, 471ff.  
   – global model 475  
   – *in silico* method for prediction 474  
   – local method 475  
   – mimicking 485  
   – substance 474  
 phototoxicity screening, artificial sunlight source 472  
 physical integration  
   – complete 21  
   – federated 22  
 physicochemical determinant 206  
 physiologically based pharmacokinetics (PBPK) 131, 222ff.  
   – limitation 237  
 PipelinePilot 60, 307  
 PK/PD (pharmacokinetic pharmacodynamic) model 225ff., 375  
   – limitation 237  
 PK-Sim 224  
 plasma protein binding (PPB) 197ff., 213  
   – *in silico* prediction 206  
   – measurement 201  
 polar surface area (PSA) 30  
 polarity 103  
 polychlorinated biphenyl (PCB) 450  
 polychlorinated dibenzo-*p*-dioxin (PCDD) 450  
 polychlorinated dibenzofuran (PCDF) 450  
 polymorphism, CYP enzyme 44  
 polymyxin B1 33  
 popliteal lymph node assay (PLNA) 448  
 potassium channel 390  
 potency 290  
 potency screen, plasma protein binding 197ff.  
 prediction 96  
   – activity spectra for substances (PASS) 314  
   – compound promiscuity 304  
   – 3D molecular structure 95  
   – drug-likeness 25ff.  
   – drug metabolism 145ff.  
   – *in silico* 96  
   – *in vivo* absorption 135  
   – ionic species 97  
   – model 27, 96f.  
   – phototoxicity 474  
   – target 312  
   – toxicogenomics 457  
   – volume of distribution (VD) 210  
 Predictive Data Miner 252  
 predictive toxicology 337  
 pregnane X receptor (PXR) 177ff., 369  
 principal component analysis (PCA) 53  
 process logistics 3  
 profiling  
   – adverse immune effect 439ff.  
   – hit 265  
   – lead optimization 266  
   – library 265  
   – primary assay 49  
   – test 253  
 profiling assay quality 48  
 progression, criteria 160  
 promiscuity, *see* compound promiscuity  
 prontosilto 146  
 protein binding 454  
 PubChem 316  
 purity 249
- q**
- quantitative structure–activity relationships (QSAR) 252, 451, 474f.  
   – 3D QSAR model 133
- r**
- RAD54-GFP yeast assay 260  
 radiolabeled soft nucleophile trapping 158  
 radiolabeled covalent binding experiment 160

- radioligand binding 393
  - radiometric assay 156
  - rapid equilibrium dialysis (RED) 204
  - RCA, *see* root cause analysis
  - reaction phenotyping 179
  - reactive metabolite 153ff., 346
    - minimizing risk 159
    - trapping 348
  - reactive nitrogen species (RNS) 357
  - reactive oxygen species (ROS) 357ff., 478f.
    - photoinduced 478
  - reference compound 46
  - relative activity factor (RAF) 181
  - reporter gene assay 178, 263
  - reverse-phase liquid chromatography (RP-LC) 100
  - risk assessment 401
    - integrated 387, 401
    - integrative 61
  - RNA-based technique 10
  - root cause analysis (RCA) 13
  - Rowland–Matin equation 182ff.
  - rubidium efflux 393
  - rule of five 30
- s**
- $\Sigma f$  method 93
  - Saccharomyces cerevisiae* mutation assay 256
  - safety assay
    - sensitivity 58
    - specificity 58
  - safety assessment 260
  - safety attrition 326
  - safety margin 338, 403
    - plasma protein binding 197ff.
  - safety pharmacology data 298
    - meta data analysis 304
  - safety pharmacology profiling 273ff.
    - *in vitro* 273
  - safety profiling assay 56
  - scintillation proximity assay (SPA) 177, 284, 392
  - screening
    - ADME/Tox 17ff.
    - genotoxicity assay 253
    - hierarchical 9
    - parallel 9
  - screening data 261
    - positive 262
  - secondary pharmacology 274
  - sentinel 49
  - sensitization, chemical 454
  - sertindole 399
  - serum chemistry marker 370
  - Simcyp 224
  - simulated biological fluid, solubility 89
  - single-cell monitoring 333
  - skin, reconstructed 485
  - SMARTS 34
  - sodium taurocholate 89
  - software 18, 93
  - solid phase microextraction (SPME) 206
  - solubility 49, 71ff.
    - aggregation 83
    - calculation 77
    - determination 74
    - equilibrium 50
    - function of pH 79
    - influence 72
    - kinetic 50
    - low 129
    - non-aqueous solvent 78
  - solubility assay 50
  - solubility product 85
  - solvatochromic equation 96
  - solvent accessible surface area (SASA) 95
  - SpotFire 60
  - stress response 330
  - structure–activity relationship (SAR) 354, 475
  - structure-based drug design (SBDD) 168
  - structure–toxicity relationship 353
- t**
- 3T3 NRU assay 481ff.
  - target annotation 276
  - target compound profile (TCP) 41
  - target family 34
  - target hit rate (THR) 58, 289, 305
  - target organ, reconstructed skin 485
  - target prediction, database 312
  - target selection 275
  - terfenadine 62
  - testing
    - hierarchical 45
    - tiered cascade 419ff.
  - thallium influx 393
  - therapeutic index (TI) 42, 290, 403
  - thiazolidinedione (TZD) 354
  - threshold of toxicological concern (TTC) 250
  - TLOGP method 95
  - TOPKAT 251, 451
  - topological descriptor 95
  - TOPS-MODE 451
  - toxicity
    - genetic, *see* genetic toxicity
    - idiosyncratic 153



- mitochondrial 356
- toxicogenomics 456
- prediction 457
- toxicology 56
- predictive 337
- screening 325ff.
- toxicophore 352
- transactivation assay 178
- TRANSIL technology 206
- translocation 245
- transporter 51
- trapping assay 155
- trend analysis 60
- tri-layer PAMPA 127
- triangulation 396f.
- trogliatazone 354ff.

**u**

- unstirred water layer (UWL) 117
- permeability 128
- UV exposure 480ff.

**v**

- validation 336
- biomarker 374
- human toxicity data 336

- vancomycin 33
- variability, interlaboratory 129
- vascular leak syndrome (VLS) 450
- vehicle 248
- villi expansion (VE) 119
- virtual filtering 92
- VLOGP method 96
- volume of distribution (VD) 208ff.
- prediction 210
- prediction of human VD from animal pharmacokinetic data 210
- prediction of human VD from *in silico* method 213
- prediction of human VD from *in vitro* data 212
- steady state (VD<sub>ss</sub>) 208ff.

**w**

- whole-process approach 20

**x**

- xenobiotic metabolism 147

**y**

- yeast model, photobiology 480
- yeast mutation assay 256

